Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
Open Access
- 1 January 2018
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 9 (22), 4099-4107
- https://doi.org/10.7150/jca.27408
Abstract
We conducted this study to determine whether immunoscore system (IS) predicts survival in patients with metastatic renal cell carcinoma (mRCC). A total of 218 mRCC patients treated with sunitinib or sorafenib in Zhongshan Hospital, Fudan University were recruited during 2007-2017, retrospectively. CD8, CD4, Treg, PD-1 and PD-L1 expression were evaluated by immunohistochemical staining of paraffin embedded slide. Kaplan-Meier method and COX regression model were used in survival analyses. Multivariate analyses demonstrated that expressions of CD8, Treg, PD-1 and stromal PD-L1 (sPD-L1) expressions were independent predictive factors for OS, thus IS was established containing these four immunological factors. Subsequent analysis revealed that performance of IS provided good differentiation of OS and PFS. Besides, multivariate analysis identified IS as an independent prognostic factor for OS (p<0.001) and PFS (p=0.002). IS, compared with International mRCC Database Consortium (IMDC) risk model, and provided better prediction ability for OS. Results suggested that IS was a powerful prognostic factor for OS and PFS in patients with mRCC treated with tyrosine kinase inhibitors. And IS can be used as essential supplement to IMDC for outcome prediction in mRCC patients.This publication has 25 references indexed in Scilit:
- Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimensOncotarget, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of DiseaseClinical Cancer Research, 2015
- A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal CancerEuropean Urology, 2015
- CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8+ T cell frequency and patient survivalHuman Immunology, 2014
- The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal CancerClinical Cancer Research, 2013
- The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic ParametersThe American Journal of Surgical Pathology, 2013
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009